Complement system modulation in age-related macular degeneration: navigating failures, building future successes

Area of Science:

• Ophthalmology
• Immunology
• Genetics

Background:

• Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss in older adults.
• Dysregulation of the complement system is linked to AMD development and progression.
• Current complement inhibition therapies are approved for geographic atrophy, a dry form of AMD.

Purpose of the Study:

• To review the current state of complement-targeted therapies for AMD.
• To identify challenges and future directions for AMD treatment.

Main Methods:

• Literature review of complement system involvement in AMD.
• Analysis of current complement inhibition therapies' efficacy and limitations.
• Discussion of emerging therapeutic strategies and biomarkers.

Main Results:

• Complement inhibitors moderately slow geographic atrophy lesion growth.
• Current treatments do not improve visual function.
• Significant challenges include intervention timing, delivery, safety, biomarkers, and response variability.

Conclusions:

• Complement modulation is a promising but complex therapeutic strategy for AMD.
• Future advancements require earlier intervention, precision medicine with genetic and imaging biomarkers.
• Exploring combination or gene-based therapies is crucial for improved AMD treatment outcomes.